AI-powered search
Try Polaris, our new AI-powered search!

Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib?

Featuring Cheri Frey, MD |

Assistant Professor, Dermatology & Residency Program Director 
Director of Cosmetic Dermatology
Howard University
Washington, DC

| Published June 01, 2024